Excelsior Biopharma Valuation

Is 6496 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6496 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6496's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6496's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6496?

Key metric: As 6496 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6496. This is calculated by dividing 6496's market cap by their current revenue.
What is 6496's PS Ratio?
PS Ratio	1.7x
Sales	NT$830.35m
Market Cap	NT$1.39b

6496 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.8x
Enterprise Value/EBITDA	-65.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6496's PS Ratio compare to its peers?

The above table shows the PS ratio for 6496 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.2x
4745 Cowealth Medical Holding	0.4x	n/a	NT$1.6b
4173 Arich Enterprise	1.3x	n/a	NT$1.5b
3118 Level Biotechnology	1.5x	n/a	NT$1.0b
6130 Shangya Technology	5.5x	n/a	NT$1.1b
6496 Excelsior Biopharma	1.7x	n/a	NT$1.4b

Price-To-Sales vs Peers: 6496 is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does 6496's PS Ratio compare vs other companies in the TW Healthcare Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
4745 Cowealth Medical Holding	0.4x	n/a	US$48.82m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 6496 is expensive based on its Price-To-Sales Ratio (1.7x) compared to the TW Healthcare industry average (1.7x).

Price to Sales Ratio vs Fair Ratio

What is 6496's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6496 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6496's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Universal Vision Biotechnology

NT$17.8b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$210.50

-4.1%

-25.1%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$138.50

-0.4%

1.5%

Ma Kuang Healthcare Holding

NT$1.3b

An investment holding company, provides medical services in Taiwan and internationally.

4139

NT$30.35

1.0%

-19.1%